![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Ely Lilly Offers $35 Insulin Co-Pay in Response to COVID-19
Ely Lilly Offers $35 Insulin Co-Pay in Response to COVID-19
![Insulin Needle and Bottle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Insulin-needle-bottle.gif?t=1582840703&width=430)
Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to the diabetes drug during the COVID-19 crisis.
The new co-pay card program covers most Lilly insulins, including all Humalog formulations, and all existing cards have been reset to a $35 co-pay.
The cards are not available for patients with government insurance, such as Medicaid and Medicare, or those getting state assistance.
Upcoming Events
-
21Oct